Delta-9-tetrahydrocannabinol pharmacokinetics;Pharmacocinétique du delta-9-tétrahydrocannabinol (THC)

Annales Pharmaceutiques Francaises

Volumn 66, Issue 4, 2008, Pages 232-244

  Goulle J P ^a,b   Saussereau, E ^a   Lacroix, C ^a  

^a LE HAVRE HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Blood; Pharmacokinetics; Tetrahydrocannabinol; Urine

Indexed keywords

ALCOHOL; CANNABINOID; CANNABIS; DRONABINOL; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ABSORPTION; ARTICLE; BIOAVAILABILITY; BLOOD ANALYSIS; BLOOD LEVEL; BODY FAT; CANNABIS SMOKING; CIGARETTE SMOKING; FECES LEVEL; GAS CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLISM; METABOLITE; TISSUE DISTRIBUTION; TISSUE LEVEL; URINARY EXCRETION; ANIMAL; REVIEW;

ABSORPTION; ANIMALS; HUMANS; MARIJUANA SMOKING; PSYCHOTROPIC DRUGS; TETRAHYDROCANNABINOL; TISSUE DISTRIBUTION;

EID: 58149171511     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2008.07.006     Document Type: Article

References (81)

1. Mura P., Brunet B., Dujourdy L., Paetzold C., Bertrand G., Sera B., et al. Cannabis d'hier et cannabis d'aujourd'hui. Augmentation des teneurs en THC de 1993 à 2004 en France. Ann Toxicol Anal 18 (2006) 3-6
2. Huestis M. Pharmacokinetics of THC in inhaled and oral preparations. In: Nahas G.G., Sutin K.M., Harvey D., and Agurell S. (Eds). Marihuana and medicine. Totowa (1999), Humana Press, New Jersey 105-116
3. Agurel S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespi H., et al. Pharmacokinetics and metabolism of 1-tétrahydrocannabinol and others cannabinoids with emphasis on man. Pharmacol Rev 38 (1986) 21-43
4. Inversen L.L. The science of marijuana (2000), University Presse, Oxford pp. 37
5. Lindgren J.E., Ohlsson A., Agurell S., Hollister L., and Gillespie H. Clinical effects and plasma levels of delta 9-tétrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74 (1981) 208-212
6. Azorloza J.L., Heishman S.J., Stizer M.L., and Mahaffey J.M. Marijuana smoking: Effect of varying delta 9-tetrahydrocannabinol content and number of puff. J Pharmacol Exp Ther 261 (1992) 114-122
7. Huestis M.A., Sampson A.H., Holicky B.J., Henningfield J.E., and Cone E.J. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52 (1992) 31-41
8. Azorlosa J.L., Greenwald M.K., and Stize M.L. Marijuana smoking: Effects of varying puff volume and breath hold duration. J Pharmacol Exp Ther 272 (1995) 560-569
9. Wall M.E., Sadler B.M., Brine D., Taylor H., and Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34 (1983) 352-363
10. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 (2002) 564-578
11. Ménétrey A., Augsburger M., Favrat B., Pin M.A., Rothuizen L.E., Appenzeller M., et al. Assessment of driving capability through the use of clinical and psychomotor test in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with twenty or 60 mg delta 9-THC. Anal Toxicol 29 (2005) 327-338
12. Ohlsson A., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., and Gillespie H.K. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28 (1980) 409-416
13. Timpone J.G., Wright D., Li N., Egorin M.J., Enama M.E., Mayers J., et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome AIDS. Res Hum Retroviruses 13 (1997) 305-315
14. Sporkert F. Pragst F, Poner CJ, et al. Pharmacokinetic investigation of delta-9-tetrahydrocannabionl and its metabolites after single administration of 10 mg Marinol in attendance of a psychiatric study with 17 volunteers. Poster at the 39th Annual International Meeting. International Association of Forensic Toxicologists 2001; Aug 26-30, Prague, Szech Republic.
15. Law B., Mason P.A., Moffat A.C., Gleadle R.I., and King L.J. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 36 (1984) 289-294
16. Frytak S., Moertel C.G., and Rubin J. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68 (1984) 1427-1431
17. Hollister L.E., Gillespie H.K., Ohlsson A., Lindgren J.E., Wahlen A., and Agurell S. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxications. J Clin Pharmacol 21 (1981) 171S-177S
18. Agurell S., and Leander K. Stability, transfer and absorption of cannabinoïd constituents of cannabis (hashish) during smoking. Acta Pharma Suec 8 (1971) 391-402
19. ElSohly M.A., Stanford D.F., Harland E.C., Hikal A.H., Walker L.A., and Little T.L. Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 80 (1991) 942-945
20. Brenneisen R., Egli A., Elsohly M.A., Henn V., and Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34 (1996) 446-452
21. Widman M., Agurell S., Ehrnebo M., and Jones G. Binding of (+)- and (minus)-delta-1-tetrahydrocannabinols and (minus)-7-hydroxy-delta-1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharmacol 26 (1974) 914-916
22. Giroud C., Ménétrey A., Augsburger M., Buclin T., Sanchez-Mazas P., and Mangin P. Delta(9) - THC, 11-OH-Delta (9) -THC and Delta (9)-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci Int 123 (2001) 159-164
23. Wahlqvist M., Nilsson I.M., Sandberg F., and Agurell S. Binding of delta-1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol 19 (1970) 2579-2584
24. Hunt C.A., and Jones R.T. Tolerance and disposition of tetrahydrocannabionol in man. J Pharmacol Exp Ther 215 (1980) 35-44
25. Lemberger L., Tamarkin N.R., Axelrod J., and Kopin I.J. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 173 (1971) 72-74
26. Sticht G., Käferstein H., and Grundberiffe. Toxicokinetik und toxikodynamik. In: Berghaus G., and Krüger H.P. (Eds). Cannabis im StraBenverkehr (1998), Stuttgart, Gustav Fischer 1-11
27. Kelly P., and Jones R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16 (1992) 228-235
28. Ryrfeldt A., Ramsay C.H., Nilsson I.M., Widman M., and Agurell S. Whole-body autoradiography of Δ 1-tetrahydrocannabinol and Δ (6)-tetrahydrocannabinol in mouse: pharmacokinetic aspects of Δ 1-tetrahydrocannabinol and its metabolites. Acta Pharm Suec 10 (1973) 13-28
29. Ho B.T., Fritchie G.E., Kralik P.M., Englert L.F., McIsaac W.M., and Idänpään-Heikkilä J. Distribution of tritiated-1 delta 9-tetrahydrocannabionol in rat tissues after inhalation. J Pharm Pharmacol 22 (1970) 538-539
30. Nahas G.G. The pharmacokinetics of THC in fat and brain: resulting functional response to marihuana smoking. Hum Psychopharmacol 16 (2001) 247-255
31. Gill E.W., and Jones G. Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice: correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 21 (1972) 2237-2248
32. Chiang C.N., and Rapaka R.S. Phamacokinetics and disposition of cannabinoids. NIDA Res Monogr 79 (1987) 173-188
33. Schou J., Prockop L.D., Dahlstrom G., and Rohde C. Penetration of delta-9-tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol through the blood-brain barrier. Acta Pharmacol Toxicol 41 (1977) 33-38
34. Kreuz D.S., and Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 179 (1973) 391-393
35. Harvey D.J., Leuschner J.T., and Paton W.D. Gas chromatographic and mass spectrometric studies on the metabolism and pharmacokinetics of delta 1-tetrahydrocannabinnol in the rabit. J Chromatogr 239 (1982) 243-250
36. Harvey D.J. Absorption, distribution and biotransformation of the cannabinoids. In: Nahas G.G., Sutin K.M., Harvzy D., and Agurell S. (Eds). Marihuana and medicine (1999), Humana Press, Totowa, New Jersey 91-103
37. Huestis M.A., Henningfield J.E., and Cone E.J. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16 (1992) 276-282
38. Blackard C., and Tennes K. Human placental transfer of cannabinoïdes [letters]. N Engl J Med 311 (1984) 797
39. Bailey J.R., Cunny H.C., Paule M.G., and Slikker W. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90 (1987) 315-321
40. Martin B.R., Dewey W.L., Harris L.S., and Beckner J.S. 3H-delta9-tetrahydrocannabinol distribution pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 17 (1977) 457-470
41. Hutchings D.E., Martin B.R., Gamagaris Z., Miller N., and Fico T. Plasma concentrations of delta9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 44 (1989) 697-701
42. Abrams R.M., Cook C.E., Davis K.H., Niederreither K., Jaeger M.J., and Szeto H.H. Plasma delta 9-tetrahydrocannabinol in pregnant sheep and foetus after inhalation of smoke from a marijuana cigarette. Alcohol Drug Res 6 (1985-1986) 361-369
43. Elsohly M.A., and Feng S. Delta 9-THC metabolites in meconium: identification of 11-OH-delta 9-THC, 8 beta, 11-diOH-delta 9-THC, and 11-nor-delta9-THC-9-COOH as major metabolites of delta 9-THC. J Anal Toxicol 22 (1998) 329-335
44. Perez-Reyes M., DiGuiseppi S., Davis K.H., Schindler V.H., and Cook C.E. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 31 (1982) 617-624
45. Harvey D.J., and Brown N.K. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 40 (1991) 533-540
46. Agurell S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespie H., et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1986) 21-43
47. Barnett G., Licko V., and Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology 85 (1985) 51-56
48. Martin B.R., and Cone E.J. Chemistry and pharmacology of cannabis. In: Kalant H., Corrigall W., and Smart R. (Eds). The Health effects of cannabis (1999), Centre for Addiction and Mental Health, Toronto 21-68
49. Ohlsson A., Lindgren J.E., Wahlén A., Agurell S., Hollister L.E., and Gillespie H.K. Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9 (1982) 6-10
50. Schwartz R.H., Hayden G.F., and Riddile M. Laboratory detection of marijuana use: experience with a photometric immunoassay to measure urinary cannabinoids. Am J Dis Child 139 (1985) 1093-1096
51. Ellis Jr. G.M., Mann M.A., Judson B.A., Schramm N.T., and Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38 (1985) 572-578
52. Lafolie P., Beck O., Blennow G., Boréus L., Borg S., and Elwin C.E. Importance of creatinine analyses of urine when screening of abusers drugs. Clin Chem 37 (1991) 1927-1931
53. Kielland K.B. Urinary excretion of cannabis metabolites. Tidsskr Nor Laegeforen 112 (1992) 1585-1631
54. Huestis M.A., and Cone E.J. Urinary excretion half-life of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans. Ther Drug Monit 20 (1998) 570-576
55. Johansson E., and Halldin M.M. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 13 (1989) 218-223
56. Williams P.L., and Moffat A.C. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32 (1980) 445-448
57. Alburges M.E., and Peat M.A. Profiles of delta 9-tetrahydrocannabinol metabolites in urine of marijuana users: preliminary observations by high performance liquid chromatography-radioimmunoassay. J Forensic Sci 31 (1986) 695-705
58. Manno J.E., Manno B.R., Kemp P.M., Alford D.D., Abukhalaf I.K., McWilliams M.E., et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of 9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 25 (2001) 538-549
59. Garrett E.R., and Hunt C.A. Physiochemical properties, solubility, and protein binding of 9-tetrahydrocannabinol. J Pharm Sci 63 (1974) 1056-1064
60. Verstraete A., and Samyn N. Le dépistage biologique d'une conduite sous influence. Ann Toxicol Anal 15 (2003) 83-91
61. Musshoff F., Driever F., Lachenmeier K., Lachenmeier D.W., Banger M., and Madea B. Results of analysis for drugs of abuse and comparison with self-reports and urines tests. Forensic Sci Int 156 (2006) 118-123
62. Kauert G.F., Ramaekers G., Schneider E., Moeller M.R., and Toennes S.W. Pharmacokinetic properties of delta 9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol 31 (2007) 288-293
63. Huestis M.A., Henningfield J.E., and Cone E.J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 16 (1992) 283-290
64. Daldrup T. Cannabis im Strassenverkehr. Abschlussbericht des im Auftrage des Ministeriums für Wirtschaft und mitttelstand Technologie und Verkehr des Landes Nordrhein-Westfalen durchgeführten untersuchungsvorhabens 1996;44-59.
65. Harder S., and Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 35 (1997) 155-159
66. Cone E.J., and Huestis M.A. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 15 (1993) 527-532
67. Mura P., Kintz P., Ludes B., Gaulier J.M., Marquet P., Martin-Dupont S., et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subject: results of a French collaborative study. Forensic Sci Int 133 (2003) 79-85
68. McBay A.J. Drug concentrations and traffic safety. Alcohol Drugs Driving 2 (1986) 51-59
69. Mura P., Kintz P., Dumestre V., Raul S., and Hauet T. THC can be detected in brain while absent in blood. J Anal Toxicol 29 (2005) 692-693
70. Deveaux M., Goullé J.P., and Lhermitte M. Dosage des stupéfiants dans le sang des conducteurs impliqués dans un accident de la circulation : interprétation de résultats, définition de seuils. Ann Toxicol Anal 15 (2003) 98-107
71. Perez-Reyes M. Marijuana smoking: Factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr 99 (1990) 42-62
72. Lindgren J.E., Ohlsson A., Agurell S., Hollister L., and Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 74 (1981) 208-212
73. Huestis M.A., Mitchell J.M., and Cone E.J. Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 19 (1995) 443-449
74. Smith-Kielland A., Skuterud B., and Morland J. Urinary excretion of 11-nor-carboxy-delta 9-tetrahydrocannabinol and cannabinoids and in frequent and infrequent drug users. J Anal Toxicol 23 (1999) 323-332
75. Dackis C.A., Pottash A.L., Annitto W., and Gold M.S. Persistence of urinary marijuana levels after supervised abstinence. Am J Psychiatry 139 (1982) 1196-1198
76. Ellis Jr. G.M., Manne M.A., Judson B.A., Schramm N.T., and Tashchian A. Excretion patterns of cannabinoïd metabolites after last use in a group of chronic users. Clin Pharmacol Ther 38 (1985) 572-578
77. Cone E.J., Johnson R.E., Paul B.D., Mell L.D., and Mitchell J. Marijuana-laced brownies: Behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 12 (1988) 169-175
78. Kelly P., and Johns R.T. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16 (1992) 228-235
79. Huestis M.A., Mitchell J.M., and Cone E.J. Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked dose of marijuana. J Anal Toxicol 20 (1996) 441-452
80. Reiter A., Hake J., Meissner C., Rohwer J., Friedrich H.J., and Oehmichen M. Time of drug elimination in chronic drug abusers. Case study of 52 patients in a "low-step" detoxification ward. Forensic Sci Int 119 (2001) 248-253
81. Goullé J.P., and Lacroix C. Mise en évidence des cannabinoïdes : quel milieu biologique ?. Ann Pharm Fr 64 (2006) 192-196